Guardian Pharmacy (GRDN) Services announced the launch of a proposed underwritten public offering of 5M shares of its Class A common stock, consisting of 3.98M shares being offered by certain selling stockholders and 1.02M newly issued shares being offered by Guardian as part of a non-dilutive “synthetic secondary” transaction. BofA Securities, Jefferies and Raymond James are acting as joint bookrunners for the proposed offering. Stephens and Oppenheimer & Co. are acting as co-managers for the proposed offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRDN:
- Guardian Pharmacy price target raised to $38 from $35 at Oppenheimer
- Guardian Pharmacy price target raised to $38 from $34 at Truist
- Guardian Pharmacy Services Posts Strong Growth Amid Headwinds
- Guardian Pharmacy reports Q4 EPS 37c, consensus 27c
- Guardian Pharmacy backs FY26 revenue view of $1.40B-$1.42B, consensus $1.42B
